Trace amine-associated receptor 1 (TAAR1) agonists for psychosis: protocol for a living systematic review and meta-analysis of human and non-human studies.

Autor:	Siafis S; Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany., McCutcheon R; Department of Psychiatry, University of Oxford, Oxford, England, UK.; Oxford Health NHS Foundation Trust, Oxford, England, UK.; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England, UK., Chiocchia V; Institute of Social and Preventive Medicine, University of Bern, Bern, Canton of Bern, Switzerland., Ostinelli EG; Department of Psychiatry, University of Oxford, Oxford, England, UK.; Oxford Health NHS Foundation Trust, Oxford, England, UK.; Oxford Precision Psychiatry Lab, University of Oxford, Oxford, England, UK., Wright S; Department of Psychiatry, Stellenbosch University, Stellenbosch, Western Cape, South Africa., Stansfield C; EPPI Centre, Social Research Institute, University College London, London, England, UK., Juma DO; My Mind Our Humanity, Mombasa, Kenya., Mantas I; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden., Howes OD; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England, UK., Rutigliano G; Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, England, UK., Ramage F; Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK., Tinsdeall F; Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK., Friedrich C; Department of Psychiatry, University of Oxford, Oxford, England, UK.; Oxford Precision Psychiatry Lab, University of Oxford, Oxford, England, UK., Milligan L; MQ Mental Health Research, London, UK., Moreno C; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, ISCIII, School of Medicine, Universidad Complutense de Madrid, Madrid, Community of Madrid, Spain., Elliott JH; Cochrane Australia, School of Public Health and Preventive Medicine, Monash University, Clayton, Victoria, Australia.; Future Evidence Foundation, Melbourne, Australia., Thomas J; EPPI Centre, Social Research Institute, University College London, London, England, UK., Macleod MR; Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK., Sena ES; Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK., Seedat S; Department of Psychiatry, Stellenbosch University, Stellenbosch, Western Cape, South Africa., Salanti G; Institute of Social and Preventive Medicine, University of Bern, Bern, Canton of Bern, Switzerland., Potts J; Department of Psychiatry, University of Oxford, Oxford, England, UK.; Oxford Precision Psychiatry Lab, University of Oxford, Oxford, England, UK., Cipriani A; Department of Psychiatry, University of Oxford, Oxford, England, UK.; Oxford Health NHS Foundation Trust, Oxford, England, UK.; Oxford Precision Psychiatry Lab, University of Oxford, Oxford, England, UK., Leucht S; Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.
Jazyk:	angličtina
Zdroj:	Wellcome open research [Wellcome Open Res] 2023 Aug 25; Vol. 8, pp. 365. Date of Electronic Publication: 2023 Aug 25 (Print Publication: 2023).
DOI:	10.12688/wellcomeopenres.19866.1
Abstrakt:	Background: There is an urgent need to develop more effective and safer antipsychotics beyond dopamine 2 receptor antagonists. An emerging and promising approach is TAAR1 agonism. Therefore, we will conduct a living systematic review and meta-analysis to synthesize and triangulate the evidence from preclinical animal experiments and clinical studies on the efficacy, safety, and underlying mechanism of action of TAAR1 agonism for psychosis. Methods: Independent searches will be conducted in multiple electronic databases to identify clinical and animal experimental studies comparing TAAR1 agonists with licensed antipsychotics or other control conditions in individuals with psychosis or animal models for psychosis, respectively. The primary outcomes will be overall psychotic symptoms and their behavioural proxies in animals. Secondary outcomes will include side effects and neurobiological measures. Two independent reviewers will conduct study selection, data extraction using predefined forms, and risk of bias assessment using suitable tools based on the study design. Ontologies will be developed to facilitate study identification and data extraction. Data from clinical and animal studies will be synthesized separately using random-effects meta-analysis if appropriate, or synthesis without meta-analysis. Study characteristics will be investigated as potential sources of heterogeneity. Confidence in the evidence for each outcome and source of evidence will be evaluated, considering the summary of the association, potential concerns regarding internal and external validity, and reporting biases. When multiple sources of evidence are available for an outcome, an overall conclusion will be drawn in a triangulation meeting involving a multidisciplinary team of experts. We plan trimonthly updates of the review, and any modifications in the protocol will be documented. The review will be co-produced by multiple stakeholders aiming to produce impactful and relevant results and bridge the gap between preclinical and clinical research on psychosis. Protocol Registration: PROSPERO-ID: CRD42023451628. Competing Interests: Competing interests: Spyridon Siafis: None Robert McCutcheon: RM received speaker/consultancy fees from Karuna, Janssen, Boehringer Ingelheim and Otsuka, and is director of a company that hosts psychotropic prescribing decision tools. Virginia Chiocchia: None. Edoardo G. Ostinelli: EGO has received research and consultancy fees from Angelini Pharma. Simonne Wright: None. Claire Stansfield: None. Damian Omari Juma: None. Ioannis Mantas: None. Oliver D. Howes: ODH is a part-time employee of H. Lundbeck A/S and has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organized by Angellini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Heptares, Global Medical Education, Invicro, Jansenn, Lundbeck, Neurocrine, Otsuka, Sunovion, Rand, Recordati, Roche and Viatris/Mylan. Neither Howes or his family have holdings/a financial stake in any pharmaceutical company Grazia Rutigliano: None. Fiona Ramage: None. Francesca Tinsdeall: None. Claire Friedrich: None. Lea Milligan: None. Carmen Moreno: CM received honoraria as a consultant and/or advisor and/or for lectures from Angelini, Compass, Esteve, Exeltis Janssen, Lundbeck, Neuraxpharm, Nuvelution, Otsuka, Pfizer, Servier and Sunovion outside the submitted work. Julian H Elliott: None. James Thomas: None. Emily Sena: None. Malcolm R. MacLeod: None. Soraya Seedat: None Georgia Salanti: None. Jennifer Potts: None. Andrea Cipriani: AC received research, educational and consultancy fees from the Italian Network for Paediatric Trials, CARIPLO Foundation, Lundbeck, and Angelini Pharma. Stefan Leucht: SL has received honoraria as advisor and/or for lectures and/or for educational material from Alkermes, Angelini, Apsen, Eisai, Gedeon Richter, Janssen, Karuna, Kynexis, Lundbeck, Medichem, Medscape, Merck Sharpp and Dome, Mitshubishi, Neurotorium, NovoNordisk, Otsuka, Recordati, Roche, Rovi, Sanofi Aventis, TEVA (Copyright: © 2023 Siafis S et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu